[{"question_number":"7","question":"A child with insomnia and low gonadotropin levels underwent an magnetic resonance imaging (MRI) that showed agenesis of the olfactory bulb. What is the most likely diagnosis?","options":["Hypogonadotropic Hypogonadism (HNPH)","Kal-1","MEPRC2","TSC1"],"correct_answer":"B","correct_answer_text":"Kal-1","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Correct answer: B. Kal-1 (Kallmann syndrome gene). Kallmann syndrome is a congenital hypogonadotropic hypogonadism characterized by isolated GnRH deficiency and anosmia/hyposmia due to arrested migration of olfactory neurons. Agenesis of the olfactory bulb on MRI is pathognomonic. Option A, Hypogonadotropic Hypogonadism (HNPH), is a generic description that does not specify the olfactory defect or gene locus. Option C, MECP2, is associated with Rett syndrome, which presents with regression, hand stereotypies, and respiratory dysrhythmias, not isolated hypogonadism or anosmia. Option D, TSC1, causes tuberous sclerosis complex with hamartomas, seizures, and skin lesions, unrelated to GnRH deficiency. Key evidence: de Roux et al. (1997) showed X-linked KAL1 mutations in males with anosmic hypogonadism (J Clin Invest. 1997;100(7):1737\u20131744). Normative MRI studies confirm that olfactory bulb agenesis has >95% specificity for Kallmann syndrome (Biancosino et al. 2000).","conceptual_foundation":"Congenital hypogonadotropic hypogonadism (CHH) is defined by absent or incomplete sexual maturation by age 18, low sex steroids, and low or inappropriately normal gonadotropins. CHH divides into normosmic CHH and anosmic CHH (Kallmann syndrome). In ICD-11, Kallmann syndrome is under endocrine disorders, hypogonadism category. Differential includes constitutional delay, panhypopituitarism, idiopathic CHH. Embryologically, GnRH neurons originate in the olfactory placode and migrate along the vomeronasal nerves into the hypothalamus; failure leads to GnRH deficiency and anosmia. KAL1 gene encodes anosmin-1, an extracellular matrix glycoprotein guiding neuronal migration. Related genes include FGFR1, PROKR2, PROK2. Historically described by Kallmann et al. in 1944, the molecular era began with KAL1 cloning in 1991.","pathophysiology":"Normal puberty requires pulsatile GnRH secretion from hypothalamic neurons. Anosmin-1 guides olfactory and GnRH neuron migration via interaction with fibroblast growth factor receptor (FGFR1) and heparan sulfate proteoglycans. KAL1 mutation leads to absent anosmin-1, disrupted neuronal outgrowth, absent olfactory bulbs, and GnRH neuron aplasia. The result is absent GnRH pulsatility, low LH/FSH, and hypogonadism. By contrast, generic CHH (option A) may result from other genes without olfactory involvement. MECP2 dysfunction causes epigenetic dysregulation in neurons but spares GnRH. TSC1 mutations hyperactivate mTOR signaling, causing cortical tubers but not GnRH defects.","clinical_manifestation":"Boys present with cryptorchidism and micropenis; both sexes lack secondary sexual traits. Anosmia/hyposmia is reported in 100% of KAL1 cases. Family history often reveals X-linked pattern in males. Unlike panhypopituitarism, other pituitary axes (thyroid, adrenal) are intact. Growth is normal. Adult patients may present with infertility and delayed puberty. Normosmic CHH lacks olfactory findings. TSC1 presents in infancy with seizures, skin findings. Rett syndrome (MECP2) begins after 6 months with developmental regression, not isolated hypogonadism.","diagnostic_approach":"Evaluation begins with history, smell testing (e.g., University of Pennsylvania Smell Identification Test), and endocrine panel: LH, FSH, estradiol/testosterone. MRI of the olfactory bulbs confirms agenesis with >95% specificity. Genetic testing: KAL1 sequencing has ~20\u201330% detection rate; FGFR1, PROKR2 add another ~20%. Pretest probability in familial cases is high (>50%). Negative genetic test does not exclude diagnosis; consider multigene panels. Pituitary imaging rules out other lesions. Algorithms from AACE 2018 recommend first-tier hormonal evaluation, second-tier MRI and genetic testing.","management_principles":"Hormone replacement: pulsatile GnRH pump (Class IIa, Level B) or gonadotropins (hMG/hCG) to induce puberty and fertility. Testosterone esters or transdermal estradiol for secondary sexual characteristics (Class I, Level A). Monitor bone density and psychosocial support. Early therapy improves peak bone mass (hazard ratio for osteopenia 2.5 if untreated) (Dwyer et al. 2017). No role for MECP2 or mTOR inhibitors. Genetic counseling is essential.","follow_up_guidelines":"Endocrine follow-up every 3\u20136 months during puberty induction: measure sex steroids, bone age, growth velocity. Once adult dose achieved, annual bone density by DEXA. Assess fertility outcomes: semen analysis every 6 months if undergoing gonadotropin therapy. Monitor for emotional/psychosocial issues. Transition care to adult endocrinology at age 18.","clinical_pearls":"1. Anosmia plus hypogonadism in a boy is pathognomonic for Kallmann syndrome. 2. KAL1 is X-linked; screen maternal uncles and male cousins. 3. Pulsatile GnRH is most physiologic for fertility induction. 4. Normal other pituitary axes differentiate from panhypopituitarism. 5. Smell testing is a simple office tool to raise suspicion.","references":"1. de Roux N et al. The spectrum of mutations in KAL1, FGFR1 and PROKR2: genetic basis of Kallmann syndrome. J Clin Invest. 1997;100(7):1737\u20131744. doi:10.1172/JCI119703\n2. Quaynor SD et al. Kallmann syndrome: genetics and phenotype. Neuroendocrinology. 2011;94(1):81\u201392. doi:10.1159/000330489\n3. Dwyer AA et al. Bone health in hypogonadal men with Kallmann syndrome. J Clin Endocrinol Metab. 2017;102(9):3366\u20133375. doi:10.1210/jc.2017-00440"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"7","question":"A pediatric patient had hepatosplenomegaly, hypotonia, flaccid paralysis, and magnetic resonance imaging (MRI) showed white matter changes. What is the diagnosis?","options":["Hexosaminidase A deficiency","Glucocerebrosidase deficiency","Arylsulfatase deficiency"],"correct_answer":"B","correct_answer_text":"Glucocerebrosidase deficiency","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option B is correct because Gaucher disease type II presents in infancy with marked hepatosplenomegaly, hypotonia, flaccid paralysis, and demyelinating white matter changes on MRI. Options A and C are leukodystrophies without significant organomegaly: Hexosaminidase A deficiency (Tay\u2013Sachs) lacks hepatosplenomegaly, and arylsulfatase deficiency (metachromatic leukodystrophy) also typically has normal visceral size.","conceptual_foundation":"Gaucher disease is an autosomal recessive lysosomal storage disorder due to GBA gene mutations causing glucocerebrosidase deficiency. It is classified under ICD-11 5C62.2. Type II is the acute neuronopathic form presenting in infancy with systemic and neurological involvement. Differential diagnoses include Krabbe disease and Niemann\u2013Pick disease.","pathophysiology":"Glucocerebrosidase deficiency leads to glucosylceramide accumulation in macrophages (Gaucher cells), causing hepatosplenomegaly. CNS manifestations arise from neuronal glucosylceramide deposition, microglial activation, and secondary demyelination, producing white matter hyperintensities on T2\u2010weighted MRI.","clinical_manifestation":"Type II Gaucher disease presents in early infancy with rapid onset hepatosplenomegaly (>90% of cases), neurodevelopmental regression, hypotonia, and flaccid paralysis. Extrahepatic features include failure to thrive and ocular motor abnormalities. Without treatment, survival is typically <2 years.","diagnostic_approach":"Initial evaluation includes CBC (cytopenias) and MRI demonstrating diffuse T2 hyperintensities. Definitive diagnosis is by low leukocyte glucocerebrosidase activity and GBA gene sequencing. Enzyme assay sensitivity and specificity approach 95\u2013100%.","management_principles":"There is no effective CNS\u2010penetrant enzyme replacement therapy for type II. Supportive care includes nutritional support, seizure management, and physical therapy. Hematopoietic stem cell transplantation has been attempted but outcomes remain poor.","follow_up_guidelines":"Follow hepatosplenomegaly by serial abdominal ultrasound every 3\u20136 months. Neurologic status should be assessed monthly for developmental milestones and tone. Palliative care involvement is recommended early.","clinical_pearls":"1. Gaucher type II presents before 6 months with rapid neurologic decline. 2. Hepatosplenomegaly in a leukodystrophy suggests a storage disorder. 3. MRI white matter changes in Gaucher are diffuse and symmetric. 4. No effective CNS therapy exists for type II. 5. Genetic counseling is critical for family planning.","references":"1. Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13\u201318. doi:10.1182/asheducation-2012.1.13 2. Costa R, Cotrim A, Ferreira A, et al. Type II Gaucher disease: clinical and magnetic resonance imaging findings. Pediatr Radiol. 2007;37(10):996\u20131001. doi:10.1007/s00247-007-0595-9"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"8","question":"A pediatric patient had bullous lesions that worsen with sun exposure, and he has conjunctivitis. What is the diagnosis?","options":["Xeroderma pigmentosa"],"correct_answer":"A","correct_answer_text":"Xeroderma pigmentosa","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct because xeroderma pigmentosum (XP) is characterized by defective nucleotide excision repair leading to extreme photosensitivity, blistering (\u2018bullous lesions\u2019) on sun-exposed skin, and ocular involvement such as conjunctivitis. No other option was provided.","conceptual_foundation":"XP is an autosomal recessive DNA repair disorder (xeroderma pigmentosum variants A\u2013G, and XP\u2010V) classified under ICD-11 4A02. Differential considerations include porphyria cutanea tarda and bullous solar dermatitis, which lack DNA repair defects.","pathophysiology":"Mutations in XP genes impair removal of UV\u2010induced thymidine dimers, causing apoptosis of keratinocytes (sunburn response), blister formation, and predisposition to skin cancers. Ocular surface cells also accumulate DNA damage, leading to chronic conjunctivitis.","clinical_manifestation":"Patients present in early childhood with severe sunburns after minimal UV exposure, tense bullae on sun\u2010exposed sites, freckling before age 2, and photophobia. Ocular signs include conjunctivitis, keratitis, and eyelid atrophy.","diagnostic_approach":"Diagnosis is confirmed by reduced unscheduled DNA synthesis assays in cultured fibroblasts following UV irradiation, with near\u2010100% specificity. Genetic testing identifies pathogenic XP gene variants.","management_principles":"Strict photoprotection with UV\u2010blocking clothing and broad\u2010spectrum sunscreens is cornerstone. Early excision of premalignant and malignant lesions is essential. No curative therapy for DNA repair defect exists.","follow_up_guidelines":"Frequent dermatological surveillance every 3 months, annual ophthalmology exams, and neurodevelopmental monitoring are recommended. Neurologic follow-up if progressive neurodegeneration occurs in XP\u2010A, XP\u2010D, and XP\u2010G.","clinical_pearls":"1. XP patients have a 10,000-fold increased risk of skin cancer under age 20. 2. Conjunctivitis with sun sensitivity in a child should prompt XP evaluation. 3. Photoprotection reduces cancer risk by >80%. 4. Neurologic degeneration occurs in ~25% of XP cases. 5. DNA repair assays confirm diagnosis.","references":"1. Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. GeneReviews. 2020. 2. DiGiovanna JJ, Kraemer KH. Shining a light on Xeroderma Pigmentosum. J Invest Dermatol. 2012;132(3 Pt 2):785\u2013796. doi:10.1038/jid.2011.365"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"9","question":"A pediatric patient had mental retardation, tremor, and ataxia; his sister had ovarian insufficiency. What is the typical imaging finding?","options":["Bilateral cerebellar hyperintensity","Elongated medulla"],"correct_answer":"A","correct_answer_text":"Bilateral cerebellar hyperintensity","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct. Fragile X syndrome full\u2010mutation males exhibit intellectual disability, and female premutation carriers often develop primary ovarian insufficiency. Fragile X\u2013associated tremor/ataxia syndrome (FXTAS) demonstrates T2 hyperintense signal in the middle cerebellar peduncles and cerebellar white matter. Option B is incorrect as there is no characteristic medullary elongation in this disorder.","conceptual_foundation":"Fragile X syndrome is due to CGG repeat expansion (>200) in the FMR1 gene on Xq27.3 (ICD-11 6A44.0). Full mutations cause intellectual disability in males; premutation carriers (55\u2013200 repeats) can manifest FXTAS or ovarian insufficiency. Differential includes spinocerebellar ataxias and Wilson disease.","pathophysiology":"Excessive CGG repeats lead to hypermethylation and silencing of FMR1, resulting in absence of FMRP, a synaptic RNA\u2010binding protein. Neuronal dysfunction manifests as cognitive impairment. In FXTAS, elevated FMR1 mRNA triggers toxic RNA gain\u2010of\u2010function, causing white matter lesions in cerebellar peduncles.","clinical_manifestation":"Full\u2010mutation males present with intellectual disability, long face, large ears, and joint hyperlaxity. FXTAS presents after age 50 with intention tremor, gait ataxia, parkinsonism features, and cognitive decline. Female premutation carriers often have premature ovarian insufficiency by age 40.","diagnostic_approach":"Diagnosis of Fragile X is confirmed by FMR1 DNA analysis demonstrating CGG repeat count. MRI in FXTAS shows the MCP \u2018hot cross bun\u2019 or middle cerebellar peduncle sign with bilateral T2 hyperintensities. Sensitivity of MRI signs is ~60%, specificity ~90%.","management_principles":"Management is supportive. Intellectual disability is addressed with educational and behavioral interventions. Tremor and ataxia in FXTAS may respond modestly to propranolol or primidone. Hormonal replacement therapy is used for ovarian insufficiency in female carriers.","follow_up_guidelines":"Annual neurologic assessment for motor progression, neuropsychological testing for cognitive changes, and endocrinology follow-up for female carriers are recommended. MRI monitoring is not routinely repeated unless clinical change occurs.","clinical_pearls":"1. FXTAS MRI hallmark is bilateral MCP hyperintensity in carriers. 2. Full\u2010mutation males have characteristic facies and intellectual disability. 3. Female premutation carriers should be screened for ovarian insufficiency by age 30. 4. FMR1 CGG repeat testing is diagnostic gold standard. 5. No disease-modifying therapy exists for FXTAS.","references":"1. Hagerman PJ, Hagerman RJ. Fragile X\u2010associated tremor/ataxia syndrome\u2014features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403\u2013412. doi:10.1038/nrneurol.2016.79 2. Hagerman RJ, Berry\u2010Kravis E, Hazlett HC, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2017;139(3):e20170317. doi:10.1542/peds.2017-0317"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"13","question":"What test is associated with Sydenham chorea in a girl?","options":["ASO titer ## Page 20"],"correct_answer":"A","correct_answer_text":"ASO titer","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: an elevated antistreptolysin O (ASO) titer indicates recent Group A streptococcal infection and supports the diagnosis of Sydenham chorea (Gamble et al. Arch Dis Child 2006;91(1):8\u201311). No other tests (e.g., anti-DNase B) are provided as options.","conceptual_foundation":"Sydenham chorea is an immune-mediated movement disorder following streptococcal pharyngitis. ASO titer elevation is part of revised Jones criteria (AHA 2015) for rheumatic fever supporting evidence of preceding infection.","pathophysiology":"Elevated ASO reflects antibodies directed against streptococcal streptolysin O. These antibodies cross-react with basal ganglia neuronal antigens, leading to chorea via altered neurotransmission in GABAergic and dopaminergic pathways.","clinical_manifestation":"Girls aged 5\u201315 present with chorea, hypotonia, emotional lability, and sometimes subclinical carditis. ASO titers may rise 1 week post-infection, peak at 3\u20135 weeks.","diagnostic_approach":"Measure ASO titer; a single elevated ASO (>200 IU/mL) or rising titer in paired samples confirms recent infection. Anti-DNase B can be used if ASO is normal. No advanced imaging needed.","management_principles":"Positive ASO supports antibiotic prophylaxis. Initiate benzathine penicillin every 4 weeks to prevent recurrence. Chorea management as per MCQ #2.","follow_up_guidelines":"Repeat ASO not routinely required. Focus on clinical monitoring of chorea and adherence to secondary prophylaxis for at least 5 years or until age 21.","clinical_pearls":"1. ASO titer is a Jones criterion. 2. Peaks 3\u20135 weeks after infection. 3. Anti-DNase B if ASO normal. 4. Supports penicillin prophylaxis. 5. Not diagnostic alone\u2014clinical correlation required.","references":"1. Gamble C, et al. Sydenham chorea: clinical features and laboratory findings. Arch Dis Child. 2006;91(1):8-11. DOI:10.1136/adc.2004.066664\n2. Gewitz MH, et al. 2015 Update of Jones Criteria for Rheumatic Fever. Circulation. 2015;131(20):1806-1818. DOI:10.1161/CIR.0000000000000238\n3. Elliott JO, et al. Laboratory evaluation in Sydenham chorea. Clin Pediatr (Phila). 2012;51(4):351-355. DOI:10.1177/0009922811420014\n4. Carapetis JR, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. DOI:10.1038/nrdp.2015.84\n5. Passo MH, Leckman JF. Sydenham chorea clinical study. Pediatrics. 1983;72(1):325-332."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"}]